Literature DB >> 12469150

Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.

Hiromitsu Yabushita1, Mitsuma Shimazu, Mari Noguchi, Tameko Kishida, Hisao Narumiya, Keizo Sawaguchi, Masayoshi Noguchi.   

Abstract

The role of vascular endothelial growth factor (VEGF) during peritoneal dissemination of ovarian carcinoma and the association with tumor microvessel density (MVD) and matrix metalloproteinase (MMP) activity was investigated. To this end, MVD, tumor tissue and ascitic fluid levels of VEGF, and MMP activity of ascitic fluid were examined in patients with ovarian cancer and benign ovarian tumor. The effect of ascites on cell growth, cell invasion activity and angiogenesis was investigated in vitro. Ascitic fluid and tumor tissue samples were obtained from 15 patients with benign ovarian tumor and 24 patients with ovarian carcinoma. Tissue extract and ascitic fluid levels of VEGF were measured using enzyme immunoassay. Tumor microvessels were detected immunohistochemically. MMP activity was measured by gelatin zymography. For the in vitro experiment, the SKOV-3 human ovarian carcinoma cell line was utilized. Cell growth was examined using MTT-assay, cell invasion activity was measured by Matrigel in vitro invasion assay, and neovascularization was assessed using an angiogenesis kit. VEGF levels in tissue extract and ascitic fluid, MVD, expression of active form MMP-2 in ascitic fluid and ascites volume were higher in ovarian cancer patients than in benign ovarian tumor patients. In addition, these were elevated in stage III and IV diseases compared to stage I and II diseases in ovarian cancer patients. MVD and expression of active form MMP-2 in ascitic fluid were closely correlated with VEGF level in tissue extracts, and MVD and ascites volume were closely correlated with VEGF level in ascitic fluid. Cell invasive activity and angiogenesis activity increased when cells were exposed to ascites. These increases were apparent when exposed to ascites obtained from ovarian cancer patients and were related to VEGF concentrations of ascitic fluid and expression of active form MMP-2 in ascitic fluid. The increased VEGF secreted from tumor cells is suggested to enhance tumor growth through angiogenesis, to produce ascites and to elevate ascitic VEGF concentrations and expression of active form MMP-2. The progression of peritoneal involvement may be induced by elevated VEGF and expression of active form MMP-2, followed by increased VEGF in the primary tumor. Control of VEGF in the primary tumor may become an effective strategy against peritoneal dissemination of ovarian carcinoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12469150

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  24 in total

1.  Vascular invasion in hepatitis B virus-related hepatocellular carcinoma with underlying cirrhosis: possible associations with ascites and hepatitis B viral factors?

Authors:  Chuan Chen; Dong-Ping Chen; Yan-Yan Gu; Liang-Hao Hu; Dan Wang; Jin-Huan Lin; Zhao-Shen Li; Jing Xu; Ge Wang
Journal:  Tumour Biol       Date:  2015-04-02

Review 2.  Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.

Authors:  Kyle J Isaacson; M Martin Jensen; Nithya B Subrahmanyam; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2017-01-31       Impact factor: 9.776

3.  The clinical significance of vascular endothelial growth factor in malignant ascites.

Authors:  Na Zhan; Wei-Guo Dong; Jing Wang
Journal:  Tumour Biol       Date:  2015-10-13

4.  Correlative studies on bFGF mRNA and MMP-9 mRNA expressions with microvascular density, progression, and prognosis of gastric carcinomas.

Authors:  Zhong-Sheng Zhao; Ji-Lin Zhou; Gen-You Yao; Guo-Qing Ru; Jie Ma; Jun Ruan
Journal:  World J Gastroenterol       Date:  2005-06-07       Impact factor: 5.742

5.  CD147, CD44, and the epidermal growth factor receptor (EGFR) signaling pathway cooperate to regulate breast epithelial cell invasiveness.

Authors:  G Daniel Grass; Lauren B Tolliver; Momka Bratoeva; Bryan P Toole
Journal:  J Biol Chem       Date:  2013-07-25       Impact factor: 5.157

6.  Clinical significance of vascular endothelial growth factor and endostatin levels in the differential diagnosis of malignant and benign ascites.

Authors:  Daye Cheng; Bin Liang; Hong Kong
Journal:  Med Oncol       Date:  2011-05-10       Impact factor: 3.064

7.  Cross-talk between vascular endothelial growth factor and matrix metalloproteinases in the induction of neovascularization in vivo.

Authors:  Quteba Ebrahem; Shyam S Chaurasia; Amit Vasanji; Jian Hua Qi; Phillip A Klenotic; Alecia Cutler; Kewal Asosingh; Serpil Erzurum; Bela Anand-Apte
Journal:  Am J Pathol       Date:  2009-11-30       Impact factor: 4.307

8.  Effect of tumor microenvironment on tumor VEGF during anti-VEGF treatment: systems biology predictions.

Authors:  Stacey D Finley; Aleksander S Popel
Journal:  J Natl Cancer Inst       Date:  2013-05-13       Impact factor: 13.506

9.  Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.

Authors:  James S Ferriss; James J Java; Michael A Bookman; Gini F Fleming; Bradley J Monk; Joan L Walker; Howard D Homesley; Jeffrey Fowler; Benjamin E Greer; Matthew P Boente; Robert A Burger
Journal:  Gynecol Oncol       Date:  2015-07-26       Impact factor: 5.482

10.  A Novel Combination of C-Reactive Protein and Vascular Endothelial Growth Factor in Differential Diagnosis of Ascites.

Authors:  Ahmed Abdel-Razik; Nasser Mousa; Hatem Elalfy; Tarek Fouad Sheta; Mahmoud Awad; Mostafa Abdelsalam; Rania Elhelaly; Rasha Elzehery; Nawal S Gouda; Waleed Eldars
Journal:  J Gastrointest Cancer       Date:  2017-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.